Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous natural progesterone for threatened abortion (phase III, Italy)
2016-002777-35Phase 3Terminated
- Sponsor
- IBSA Group
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in threatened abortion and Pregnancy-related complication comparing Progesterone arm with Placebo arm (2 arms). Primary endpoint: Ongoing pregnancy at 12 weeks of gestation. Started Aug 2018; status: terminated.
02
Drugs
progesterone
03
Conditions
threatened abortionPregnancy-related complication
Beyond the preview
Go deeper on 2016-002777-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002777-35.